# Clinical Trial of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome

> **NCT07558538** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 24 (estimated)

## Conditions studied

- ARDS (Moderate or Severe)
- ARDS (Acute Respiratory Distress Syndrome)

## Interventions

- **DRUG:** Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder)

## Key facts

- **NCT ID:** NCT07558538
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07558538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07558538, "Clinical Trial of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07558538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*